Ligand Pharmaceuticals, Inc. (LGND) Tops Q1 EPS by 9c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $283.49 -0.43%
Revenue Growth %: -32.2%
Financial Fact:
General and administrative: 6.31M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -32.2%
Financial Fact:
General and administrative: 6.31M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q1 EPS of $0.07, $0.09 better than the analyst estimate of ($0.02). Loss from continuing ops was ($0.03). Revenue for the quarter came in at $5.6 million versus the consensus estimate of $8.02 million.
Ligand Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.
Ligand Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
- Amneal gets FDA approval for lanreotide injection, launches immediately
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
